STAT3 and prostate carcinoma: When STAT3 was specifically turned off in myeloid cells expressing TLR9 from prostate cancer patients, using a CpG-STAT3 siRNA or CpG-STAT3 antisense oligonucleotides, it abrogated the immunosuppressive effects of patient-derived MDSCs on effector CD8+ T-cells [129,130].